Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + bevacizumab
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
D1:SG + VEGFRI is a combination therapeutic regimen consisting of the antibody-drug conjugate (ADC) sacituzumab govitecan and the anti-angiogenic monoclonal antibody bevacizumab. This regimen is being evaluated as a first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are classified into the 'D1' molecular subtype (basal-like immune-suppressed, or BLIS) within the FUTURE-Trop2 umbrella trial (NCT05928780). Sacituzumab govitecan targets the trophoblast cell-surface antigen 2 (TROP2) and delivers the cytotoxic payload SN-38, a topoisomerase I inhibitor, directly into tumor cells. Bevacizumab targets vascular endothelial growth factor A (VEGF-A), inhibiting tumor angiogenesis. The combination is designed to exploit the specific sensitivity of the BLIS subtype to anti-VEGF therapy while utilizing the potent anti-tumor activity of the TROP2-directed ADC.
- Brand names
- Trodelvy + Avastin
- Other names
- sacituzumab govitecan + VEGFRISG + VEGFRI
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on sacituzumab govitecan + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + bevacizumab.